A number of clinical trials have been carried out to examine the benefit of Cox-2 inhibitors, such as celecoxib, in the chemoprevention of premalignant lesions such as familial adenoma polyposis (FAP) [30], Barrett’s esophagus [31], and oral premalignant lesions [32], as well as in the treatment of advanced cancers in combination with chemotherapy [33-36]. The gene discussed is PTGS2; the disease is cancer.